Nicholas Maragakis

Q Therapeutics, Inc. engages in developing adult stem cell therapies to treat debilitating disease of the central nervous system. Its product, Q-Cells will undergo first-in-human trials for ALS. The firm’s therapeutic strategy is intended to restore the normal activity of neurons by providing the support functions present in healthy central nervous system tissue. The company was founded by Dennis B. Farrar, Mahendra S. Rao, Mani Ramaswami, and Steven Goldman on March 28, 2002 and is headquartered in Salt Lake City, UT.

Q Therapeutics, Inc. engages in developing adult stem cell therapies to treat debilitating disease of the central nervous system. Its product, Q-Cells will undergo first-in-human trials for ALS. The firm’s therapeutic strategy is intended to restore the normal activity of neurons by providing the support functions present in healthy central nervous system tissue. The company was founded by Dennis B. Farrar, Mahendra S. Rao, Mani Ramaswami, and Steven Goldman on March 28, 2002 and is headquartered in Salt Lake City, UT.

Q Therapeutics, Inc. engages in developing adult stem cell therapies to treat debilitating disease of the central nervous system. Its product, Q-Cells will undergo first-in-human trials for ALS. The firm’s therapeutic strategy is intended to restore the normal activity of neurons by providing the support functions present in healthy central nervous system tissue. The company was founded by Dennis B. Farrar, Mahendra S. Rao, Mani Ramaswami, and Steven Goldman on March 28, 2002 and is headquartered in Salt Lake City, UT.

Q Therapeutics, Inc. engages in developing adult stem cell therapies to treat debilitating disease of the central nervous system. Its product, Q-Cells will undergo first-in-human trials for ALS. The firm’s therapeutic strategy is intended to restore the normal activity of neurons by providing the support functions present in healthy central nervous system tissue. The company was founded by Dennis B. Farrar, Mahendra S. Rao, Mani Ramaswami, and Steven Goldman on March 28, 2002 and is headquartered in Salt Lake City, UT.

Q Therapeutics, Inc. engages in developing adult stem cell therapies to treat debilitating disease of the central nervous system. Its product, Q-Cells will undergo first-in-human trials for ALS. The firm’s therapeutic strategy is intended to restore the normal activity of neurons by providing the support functions present in healthy central nervous system tissue. The company was founded by Dennis B. Farrar, Mahendra S. Rao, Mani Ramaswami, and Steven Goldman on March 28, 2002 and is headquartered in Salt Lake City, UT.